In this week’s Impact Factor, Dr. F. Perry Wilson delves into the latest study on GLP-1 receptor agonists—drugs like Ozempic and Mounjaro—published in Nature Medicine. Initially developed for diabetes, these drugs have shown remarkable benefits beyond blood sugar control, including significant weight loss and reductions in smoking, alcohol use, and even compulsive behaviors. While concerns remain about long-term effects and applicability to broader populations, the study suggests that these drugs may be the ultimate “anticonsumption” therapy—addressing some of the most pressing health challenges of modern society. Could we be looking at the most transformative drug class of our era?
Keep Reading
Add A Comment